| Prognostic and Predictive Biomarkers in Ovarian Cancers (NCT03010124) | Gustave Roussy, Cancer Campus, Grand Paris | 2016-09-26 |
| ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (NCT02891824) | ARCAGY/ GINECO GROUP | 2016-09-22 |
| Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer (NCT02865811) | Dana-Farber Cancer Institute | 2016-09-15 |
| MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors (NCT02669914) | Washington University School of Medicine | 2016-09-12 |
| Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (NCT02869217) | University Health Network, Toronto | 2016-09-01 |
| Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer (NCT02867956) | Sun Yat-sen University | 2016-08-10 |
| HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life (NCT03000192) | University Hospital Southampton NHS Foundation Trust | 2016-08-01 |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT02489006) | University Health Network, Toronto | 2016-07-19 |
| Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer (NCT02672098) | Loma Linda University | 2016-07-14 |
| Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes (NCT02917798) | Memorial Sloan Kettering Cancer Center | 2016-07-12 |
| Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (NCT02828618) | AGO Study Group | 2016-07-01 |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (NCT02576665) | Tocagen Inc. | 2016-07-01 |
| Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology (NCT03219242) | Catholic University of the Sacred Heart | 2016-06-30 |
| Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic Cancers (NCT04170712) | University of Virginia | 2016-06-10 |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers (NCT02725489) | Mary Crowley Medical Research Center | 2016-06-03 |
| A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers (NCT02824328) | Duke University | 2016-06-01 |
| Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery (NCT03519165) | Tata Medical Center | 2016-06-01 |
| Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology (NCT03526809) | Cambridge University Hospitals NHS Foundation Trust | 2016-06-01 |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448) | Esperas Pharma Inc. | 2016-05-16 |
| Mesenchymal Stem Cells (MSC) for Ovarian Cancer (NCT02530047) | M.D. Anderson Cancer Center | 2016-05-16 |
| TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer (NCT02764333) | Memorial Sloan Kettering Cancer Center | 2016-05-06 |
| Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer (NCT02711865) | Hillel Yaffe Medical Center | 2016-05-01 |
| Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers (NCT02638402) | National Taiwan University Hospital | 2016-05-01 |
| Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer (NCT02758652) | Tampere University Hospital | 2016-05-01 |
| MR-HIFU for Recurrent Gynaecological Cancer (NCT02714621) | Institute of Cancer Research, United Kingdom | 2016-05-01 |
| Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (NCT02759588) | Genelux Corporation | 2016-05-01 |
| A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer (NCT02681237) | University Health Network, Toronto | 2016-04-29 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy (NCT02686463) | Shengjing Hospital | 2016-04-01 |
| An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (NCT02754115) | Tata Memorial Centre | 2016-04-01 |
| Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study (NCT02719041) | Hillel Yaffe Medical Center | 2016-04-01 |
| A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer (NCT02737787) | Memorial Sloan Kettering Cancer Center | 2016-04-01 |
| LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies (NCT02649673) | SCRI Development Innovations, LLC | 2016-03-23 |
| Guangzhou Women's Health Cohort Study (GWHCS) (NCT05506800) | Guangzhou Women and Children's Medical Center | 2016-03-03 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (NCT02631876) | ImmunoGen, Inc. | 2016-03-02 |
| Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer (NCT02567253) | University Hospital, Ghent | 2016-03-01 |
| Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin (NCT02667925) | Centre Jean Perrin | 2016-03-01 |
| Fermented Wheat Germ Extract in Women With Ovarian Cancer (NCT02411565) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-01 |
| A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer (NCT02713984) | Zhi Yang | 2016-03-01 |
| Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program (NCT02585362) | Kantonsspital Winterthur KSW | 2016-03-01 |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer (NCT02571725) | New Mexico Cancer Research Alliance | 2016-02-23 |
| A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer (NCT02608684) | Cedars-Sinai Medical Center | 2016-02-08 |
| Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation (NCT02664389) | University Hospital, Rouen | 2016-02-01 |
| Mobile Phone Technology to Increase Genetic Counseling (NCT02877862) | University of Minnesota | 2016-02-01 |
| Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer (NCT02534922) | Oncolix, Inc. | 2016-02-01 |
| Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (NCT02607813) | Novartis Pharmaceuticals | 2016-01-18 |
| Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis (NCT02769546) | Abramson Cancer Center at Penn Medicine | 2016-01-01 |
| Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer (NCT02821793) | Institut Bergonié | 2016-01-01 |
| International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) (NCT03210298) | Sabine Rhode | 2016-01-01 |
| Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125 (NCT02247323) | Beni-Suef University | 2016-01-01 |
| Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer (NCT06697613) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2016-01-01 |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) (NCT02580058) | Pfizer | 2015-12-21 |
| Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies (NCT03943316) | New Mexico Cancer Research Alliance | 2015-12-02 |
| MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer (NCT02582931) | Washington University School of Medicine | 2015-12-02 |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (NCT02431559) | Ludwig Institute for Cancer Research | 2015-12-02 |
| Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. (NCT02610075) | AstraZeneca | 2015-12-01 |
| Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host (NCT02732860) | University Health Network, Toronto | 2015-12-01 |
| Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (NCT02433626) | Critical Outcome Technologies Inc. | 2015-12-01 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (NCT02568267) | Hoffmann-La Roche | 2015-11-19 |
| Targeted Disruption to Cancer Metabolism and Growth Through Dietary Macronutrient Modification (NCT03171506) | University of Alabama at Birmingham | 2015-11-09 |
| Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) (NCT02537444) | Acerta Pharma BV | 2015-11-01 |
| Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer (NCT02562365) | Xiaohua Wu MD | 2015-11-01 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (NCT02558348) | Advenchen Laboratories, LLC | 2015-11-01 |
| Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients (NCT02470299) | New Mexico Cancer Research Alliance | 2015-10-29 |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer (NCT02440425) | H. Lee Moffitt Cancer Center and Research Institute | 2015-10-20 |
| Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer (NCT05300828) | Seoul National University Hospital | 2015-10-19 |
| Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer (NCT03656809) | NYU Langone Health | 2015-10-15 |
| Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility (NCT02133703) | Georgetown University | 2015-10-01 |
| Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer (NCT02560818) | Centre Francois Baclesse | 2015-10-01 |
| Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (NCT02526017) | Five Prime Therapeutics, Inc. | 2015-09-08 |
| Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (NCT02432378) | Roswell Park Cancer Institute | 2015-09-04 |
| Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. (NCT02560337) | Vejle Hospital | 2015-09-01 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy (NCT02948075) | NewVac LLC | 2015-09-01 |
| Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer (NCT02545010) | National University Hospital, Singapore | 2015-09-01 |
| Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (NCT02539719) | Stemcentrx | 2015-08-01 |
| A Mind-body Intervention to Improve Body and/or Self Image (NCT02531997) | University of Michigan | 2015-08-01 |
| Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02470585) | AbbVie | 2015-07-14 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (NCT02452424) | Daiichi Sankyo | 2015-07-02 |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer (NCT02483104) | AbbVie | 2015-07-01 |
| A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT02389985) | NewLink Genetics Corporation | 2015-07-01 |
| Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors (NCT02684318) | Poveda, Andrés, M.D. | 2015-07-01 |
| Efficacy of Pelvic Autonomic Nerve Monitoring System (PAMS I) in Female Patients With Pelvic Tumors (NCT02952183) | Seoul National University Hospital | 2015-07-01 |
| Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer (NCT02458001) | University College, London | 2015-07-01 |
| Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer (NCT02383251) | ARCAGY/ GINECO GROUP | 2015-06-15 |
| Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole (NCT02476955) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2015-06-09 |
| A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib (NCT02340611) | University Health Network, Toronto | 2015-06-01 |
| A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation (NCT02432690) | Sumitomo Pharma America, Inc. | 2015-06-01 |
| Platine, Avastin and OLAparib in 1st Line (NCT02477644) | Arcagy Research | 2015-05-06 |
| Pillars4Life Trial (NCT02465892) | Duke University | 2015-05-01 |
| Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients (NCT02421588) | PharmaMar | 2015-05-01 |
| WISER After Ovarian Cancer - Exercise Pilot Study (NCT02529150) | Abramson Cancer Center at Penn Medicine | 2015-05-01 |
| Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4 (NCT02326064) | Centre Hospitalier Departemental Vendee | 2015-05-01 |
| Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer (NCT02418624) | The Netherlands Cancer Institute | 2015-05-01 |
| BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older (NCT02393898) | Hoffmann-La Roche | 2015-04-23 |
| AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites (NCT02417753) | National Cancer Institute (NCI) | 2015-04-03 |
| TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors (NCT02429700) | Beihua Kong | 2015-04-01 |
| TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors (NCT02429687) | Beihua Kong | 2015-04-01 |
| T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650) | Shenzhen Second People's Hospital | 2015-04-01 |